Owners of Nemera, a French manufacturer of drug delivery devices, are exploring a potential sale of the company amid surging demand for GLP-1 weight-loss drugs and insulin therapies.
Astorg Partners and Montagu Private Equity, which together hold a majority stake in Nemera, are in early-stage discussions with financial advisors regarding a sale process expected to commence within months. The company, which produces autoinjectors, pens, inhalers, eye droppers, and pumps, operates production facilities in the United States, France, Germany, Poland, and Brazil.
Nemera’s valuation could reach approximately €3 billion (US$3.5 billion) if a sale proceeds, according to sources cited by Bloomberg. The company’s focus on devices for GLP-1 therapies and insulin delivery has positioned it to benefit from rapid growth in the sector, driven by rising obesity rates and diabetes prevalence.
Astorg and Montagu previously brought in LGT Capital Partners as a minority investor in Nemera last year. The private equity firms have not yet made a final decision on a sale, and no binding offers have been received. Advisors are expected to approach potential buyers in the coming months as the process formalizes.
Nemera’s expansion aligns with broader industry trends favoring specialized drug delivery solutions for chronic condition management. The company’s global manufacturing footprint supports its role as a key supplier to pharmaceutical clients developing next-generation therapies.
